Efficacy Of Activated Protein C To Treat Diabetic Leg Ulcers - A Randomised, Controlled Clinical Trial
Funder
National Health and Medical Research Council
Funding Amount
$519,284.00
Summary
Chronic leg ulcers are a major public health burden. Research undertaken by the CIs and funded by a NHMRC Development Grant have shown that activated protein C heals chronic wounds in animals and now in humans, and resolved mechanisms underlying activated protein C's actions. The current chronic leg ulcer trial is an essential step to validate the therapeutic use of activated protein C in wound healing, which is likely to emerge as a cost-effective treatment for this difficult health problem.
Wounds are not just the simple cuts and abrasions that can be covered with a band-aid and healed within days with no major consequence. They are a largely unrecognised spiralling epidemic that is affecting millions of people world-wide. This project aims to develop new approaches to heal wounds with research that is innovative, cross-disciplinary and has the ability to transform current approaches for wound management.
Wounds and burn injuries are frequent injuries which can lead to deformity, disfigurement and loss of movement. The cytoskeleton is integral to the wound healing process and we have shown that a specific cytoskeletal protein, Flightless I (Flii), is an important regulator of wound repair. During the course of this fellowship I plan to further my investigations into the function and regulation of Flii in wounds and aim to develop new therapies for treating wounds and reducing scar formation.